CABA is expected to report earnings to fall 1.50% to -61 cents per share on March 13
Q4'24
Est.
$-0.61
Q3'24
Missed
by $0.02
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.03
Q4'23
Missed
by $0.07
The last earnings report on November 14 showed earnings per share of -62 cents, missing the estimate of -59 cents. With 1.38M shares outstanding, the current market capitalization sits at 124.15M.
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases